Related items

The Dual-Use Regulation gives Europe a common framework for economic security, but divergent national implementation is weakening it. The same transaction can be assessed differently depending on the Member State, with guidance on cloud and software-as-a-service transfers remains unclear. Licensing processes, meanwhile, still assume a physical consignment rather than digital workflows, which sits poorly with how integrated global businesses operate. Companies bear the added cost and legal uncertainty, while the security benefit is limited. A single EU-wide approach to intangible transfers and closer alignment with the US and UK would make controls more predictable and let authorities focus on genuine risks. Read how the revision of the Dual-Use Regulation can deliver a harmonised and future-proof framework for Europe.

On Wednesday, 2 September 2026, Malte Lohan, CEO, AmCham EU met with Esteban Moctezuma Barragán, Mexican Ambassador to the European Union, Belgium and Luxembourg, for an introductory meeting to exchange views on the transatlantic business relationship. Discussions focused on opportunities to deepen EU–Mexico economic ties following the signature of the Modernised Global Agreement and interim trade agreement earlier this year. AmCham EU looks forward to continued engagement with Ambassador Moctezuma and to supporting closer EU–Mexico economic cooperation.

On Tuesday, 14 July, AmCham EU hosted Csaba Kontor, Policy Assistant, Cabinet of European Commissioner Olivér Várhelyi, for a discussion on strengthening Europe’s competitiveness in the life sciences sector. Moderated by Katerina Valkova (Bristol Myers Squibb), Chair, Healthcare Committee, AmCham EU, the exchange explored how policy decisions can support investment through research and innovation while ensuring patients in Europe can access health innovation. Participants also discussed the importance of resilient EU-US supply chains and regulatory cooperation, as well as the need to avoid divergence and provide the scale and predictability required to sustain Europe’s position as a leading destination for life sciences investment.